Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Roche for InfoPages here.
Roche - Latest News [Page 2]
Hundreds could benefit as treatment registered
Monday, 18 May 2009, 1:54 pm | Roche
Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Internationally, CLL is the most common type of leukaemia ... More >>
Roche: Tamiflu fact sheet
Wednesday, 29 April 2009, 1:17 pm | Roche
Tamiflu is an antiviral medicine. It is NOT a vaccine.1 It belongs to a group of medicines called neuraminidase inhibitors. These medicines attack the influenza virus and stop it spreading further inside your body.1 More >>
New funding could help avoid health ‘time bomb’
Tuesday, 31 March 2009, 2:39 pm | Roche
Health experts believe that new access to Pegasys® (peginterferon alfa-2a (40KD)), an effective antiviral treatment for two diseases, chronic hepatitis B and C, today announced by PHARMAC, will save thousands of lives and hundreds of millions of taxpayer ... More >>
Roche welcomes decision to fund Herceptin
Thursday, 11 December 2008, 11:06 am | Roche
Roche Products (New Zealand) Limited says it has worked productively with the government, the Ministry of Health and PHARMAC in order to supply Herceptin to New Zealand women with early HER2 positive breast cancer. More >>
Roche welcomes 52 week Herceptin funding
Wednesday, 10 December 2008, 11:18 am | Roche
Roche Products (New Zealand) Limited says it has worked productively with the government, the Ministry of Health and PHARMAC in order to supply Herceptin to New Zealand women with early HER2 positive breast cancer. More >>
New data supports case for funding MabThera®(
Monday, 10 November 2008, 2:05 pm | Roche
New data presented at the American College of Rheumatology’s annual meeting in San Francisco is good news for New Zealanders suffering from moderate to severe Rheumatoid Arthritis (RA), who have failed to respond to the most commonly prescribed biologic ... More >>
Herceptin decision continues to disappoint
Thursday, 7 August 2008, 4:18 pm | Roche
Roche Products (NZ) Ltd is very disappointed that New Zealand women with early HER2 positive breast cancer will continue to miss out on the internationally accepted 52 weeks' treatment with Herceptin(r) (trastuzumab). More >>
Judge orders review of Herceptin decision
Thursday, 3 April 2008, 3:40 pm | Roche
Roche Products (New Zealand) Limited welcomes Justice Gendall’s directive to set aside PHARMAC’s decision not to fund 52 weeks of Herceptin® for the treatment of early HER2 positive breast cancer. Svend Petersen, managing director of Roche, ... More >>
Breast cancer - Know your type
Wednesday, 24 October 2007, 3:53 pm | Roche
A leading local breast surgeon says it is important that women know about their type of breast cancer, as well as relevant testing and treatment options if they want to give themselves the best chance of a full recovery. More >>
Influenza treatment now available from pharmacies
Monday, 14 May 2007, 2:58 pm | Roche
This winter, for the first time in New Zealand, Tamiflu® (oseltamivir), an influenza (flu) treatment, will be available directly from pharmacists during the influenza season. More >>
Herceptin decision is budget based
Tuesday, 20 March 2007, 2:51 pm | Roche
Roche Products (New Zealand) Limited believes PHARMAC's decision to fund Herceptin® (trastuzumab) for nine weeks as opposed to the internationally accepted 52 week treatment period is a compromise, made for reasons of budget control as opposed to clinical ... More >>
Roche Products on Nine Weeks funding for Herceptin
Friday, 16 February 2007, 11:57 am | Roche
PHARMAC is misleading the New Zealand public and parliament about the nine week trial data. Roche is seeking an urgent meeting with the Minister of Health to discuss the implications of PHARMAC’s announcement. This has the potential to be this Labour ... More >>
New website sheds light on breast cancer
Tuesday, 17 October 2006, 3:20 pm | Roche
A new website created by Roche Products (New Zealand) Ltd providing information on a previously misunderstood, but particularly aggressive form of breast cancer went live today. This website provides New Zealand women with a new resource in the fight ... More >>
PHARMAC shuts door on 400 New Zealand women
Monday, 16 October 2006, 4:09 pm | Roche
The government’s drug funding agency PHARMAC has confirmed it will not be funding Herceptin® (trastuzumab) for women with HER2 positive early breast cancer, making New Zealand the first country in the developed world to say ‘no’ to funding the ... More >>
Australian Govt Approves Herceptin Funding
Wednesday, 23 August 2006, 5:09 pm | Roche
Roche New Zealand notes that both the Australian Government and the UK National Institute of Health and Clinical Excellence (NICE) have approved funding for Herceptin for 12 months for women with early stage HER 2 positive breast cancer Roche New Zealand ... More >>
Roche committed to securing Herceptin funding
Friday, 28 July 2006, 3:44 pm | Roche
Roche Products (New Zealand) Ltd is disappointed by PHARMAC’s decision to decline funding of Herceptin (trastuzumab) for HER2-positive early breast cancer, but the company is committed to keeping its chair at the negotiating table until a positive ... More >>
Herceptin Approved for Early Breast Cancer In NZ
Friday, 24 March 2006, 8:37 am | Roche
Herceptin (trastuzumab) Approved for Early Breast Cancer in New Zealand Roche to focus on completing funding processes. More >>
Herceptin Approved for Early Breast Cancer in NZ
Thursday, 23 March 2006, 4:46 pm | Roche
Roche Products (New Zealand) Limited is pleased to confirm it has received regulatory approval for the use of Herceptin in HER2 positive early breast cancer. New Zealand is the first country in the world to achieve formal regulatory approval. More >>
Roche Position Statement Regarding Herceptin
Tuesday, 14 February 2006, 3:27 pm | Roche
Roche Products (NZ) Limited is working proactively and constructively with both Medsafe and Pharmac to ensure the fastest possible access to Herceptin for HER2 positive women with early breast cancer in New Zealand. The regulatory submission to permit ... More >>
Tamiflu supplies prioritised for flu season, govt
Friday, 25 November 2005, 12:21 am | Roche
Auckland, 25 November 2005 – Heightened interest in avian influenza has resulted in an unprecedented increase in demand for Tamiflu worldwide. Roche is therefore taking the step of prioritising its global production capacity of Tamiflu to ensure ... More >>
